10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Source: Clinical Oncology, December 2024
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of advanced melanoma found that more than 40% of treated patients survive 10 years overall, but the 10-year melanoma-free survival approaches 100% in those with a deep response who remain in progression-free survival (PFS) at three years.
The long-term follow-up from the two trials was generally compatible. In CheckMate 067, nivolumab (Opdivo, Bristol Myers Squibb [BMS]) plus